Skip to content
Screener

Amphastar Pharmaceuticals AMPH Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$174.4MMiss by $2.7M
EPS$0.85Beat by $0.14
Revenue estimate$177.1M
EPS estimate$0.71

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$197.9M
EPS estimate$0.86

Financials

Q2 2025

Income statement

See full
Revenue$174.4M-4.4%
Gross profit$86.5M-9.1%
Operating income$42.2M-23.6%
Net income$31.0M-18.2%
EPS (diluted)$0.64-12.3%

Balance sheet

See full
Cash & equivalents$187.7M-1.0%
Total debt$655.8M+5.6%
Total assets$1.6B+8.3%

Cash flow

See full
Operating cash flow$35.6M-48.5%
CapEx$10.6M+74.8%
Free cash flow$25.0M-60.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.16B-40.8%
Enterprise value$1.63B-31.9%
P/E8.6×-3.1×
P/S1.6×-1.1×

Profitability

See full
Gross margin49.9%-4.8pp
Operating margin25.1%-7.1pp
Net margin18.6%-4.7pp
FCF margin15.5%-9.5pp

Returns & leverage

See full
Current ratio3.3×-0.2×

Segments

By geography

See full
US$167.0M-5.3%
FR$7.1M+61.3%
CN$299.0K-80.9%

By segment

See full
Finished Pharmaceutical Products$174.4M-4.4%

FAQ

When did Amphastar Pharmaceuticals report Q2 2025 earnings?
Amphastar Pharmaceuticals (AMPH) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Amphastar Pharmaceuticals's Q2 2025 revenue and EPS?
Amphastar Pharmaceuticals reported revenue of $174.4M and eps of $0.85 for Q2 2025.
Did Amphastar Pharmaceuticals beat estimates in Q2 2025?
Revenue missed the consensus estimate of $177.1M by $2.7M. EPS beat the consensus estimate of $0.71 by $0.14.
How did Amphastar Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 4.4% from $182.4M a year earlier and eps declined 9.6% from $0.94.
Where can I find Amphastar Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001297184-25-000048) and the 10-Q periodic report (0001297184-25-000050) directly on SEC EDGAR. The filing index links above go to sec.gov.